<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Align Technology (ALGN) — Investment Wiki</title>
  <meta name="description" content="Fundamental analysis of Align Technology (ALGN). Business model breakdown, revenue segments, valuation metrics, and investment thesis.">
  <meta property="og:title" content="Align Technology (ALGN) — Investment Wiki">
  <meta property="og:description" content="Fundamental analysis of Align Technology (ALGN). Business model breakdown, revenue segments, valuation metrics, and investment thesis.">
  <meta property="og:type" content="article">
  <meta name="robots" content="index, follow">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect width='100' height='100' rx='20' fill='%236C5CE7'/><text x='50' y='68' font-family='Arial' font-size='55' font-weight='bold' fill='white' text-anchor='middle'>A</text></svg>">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="../../docs/docs-styles.css">
</head>
<body>

<div class="doc-container">

  <nav class="doc-breadcrumb">
    <a href="../../index.html">Home</a>
    <span class="sep">/</span>
    <a href="../index.html">Investment</a>
    <span class="sep">/</span>
    Align Technology (ALGN)
  </nav>

  <header class="doc-header">
    <h1 class="doc-title">Align Technology (ALGN)</h1>
    <div class="doc-meta">
      <span class="tag">Company Analysis</span>
      <span>Investment Wiki — Fundamentals</span>
    </div>
  </header>

  <div class="doc-abstract">
    Align Technology (ALGN) is a global medical device company that designs, manufactures, and markets the Invisalign system, the world's leading clear aligner system, iTero intraoral scanners and services, and exocad CAD/CAM software. It pioneered the clear aligner market and continues to dominate the digital orthodontics space.
  </div>

  <div class="doc-content">

    <div class="gab-stack-infobox">
      <div class="infobox-header">Quick Reference</div>
      <table>
        <tr><td>Ticker</td><td>ALGN</td></tr>
        <tr><td>Sector</td><td>Health Care (Medical Devices)</td></tr>
        <tr><td>Market Cap</td><td>~$13.6 Billion</td></tr>
        <tr><td>P/E Ratio</td><td><span class="complexity-medium">~32x</span></td></tr>
        <tr><td>Revenue Growth</td><td>~4% YoY</td></tr>
        <tr><td>Operating Margin</td><td><span class="complexity-medium">~15%</span></td></tr>
      </table>
    </div>

    <section class="doc-section">
      <h2>1.0 Business Overview</h2>

      <p>Align Technology operates through two primary segments, creating a synergistic ecosystem for dental professionals.</p>

      <h3>Clear Aligner (Invisalign)</h3>
      <p>The core product. This segment includes the Invisalign system, a series of custom-made, clear aligners used to straighten teeth as an alternative to traditional metal braces. It accounts for approximately 80% of total revenue. Align sells directly to orthodontists and general practitioner dentists, who then treat patients.</p>

      <h3>Systems and Services (iTero & exocad)</h3>
      <p>The digital backbone. This segment includes iTero intraoral scanners and exocad CAD/CAM software. These tools allow doctors to create 3D digital impressions of patients' teeth, which are essential for treatment planning and ordering Invisalign aligners. This segment creates high switching costs for practices.</p>
    </section>

    <section class="doc-section">
      <h2>2.0 Financial Performance</h2>

      <h3>Balance Sheet Strength</h3>
      <p>Align maintains a strong balance sheet with low leverage (Debt-to-Equity ratio ~0.61). The company generates significant free cash flow, which is often deployed for share repurchases.</p>

      <h3>Margins</h3>
<pre><code><span class="code-label">reference</span>Gross Margin:      ~70%
Operating Margin:  ~15-22% (varies with FX and spending)
Net Margin:        ~10-15%

Key Driver: High gross margins reflect the premium pricing power of
Invisalign. Operating margins are sensitive to marketing spend and
foreign exchange rates.</code></pre>

    </section>

    <section class="doc-section">
      <h2>3.0 Valuation</h2>

      <p>Align typically trades at a premium valuation compared to the broader market, reflecting its market leadership, growth runway in underpenetrated international markets, and strong moat.</p>

      <h3>Valuation Metrics</h3>
      <table>
        <thead>
          <tr><th>Metric</th><th>Typical Range</th><th>Interpretation</th></tr>
        </thead>
        <tbody>
          <tr><td><strong>P/E Ratio</strong></td><td>30x – 40x</td><td>Premium multiple for a market leader with growth potential.</td></tr>
          <tr><td><strong>PEG Ratio</strong></td><td>~2.0</td><td>Suggests valuation is somewhat demanding relative to near-term growth.</td></tr>
          <tr><td><strong>FCF Yield</strong></td><td>~4.5%</td><td>Solid yield, indicating strong cash generation relative to price.</td></tr>
        </tbody>
      </table>

      <div class="callout callout-note">
        Align's "moat" consists of network effects (doctor training), a massive dataset of millions of patient cases used to train its AI algorithms, and a sticky digital ecosystem (iTero scanners).
      </div>
    </section>

    <section class="doc-section">
      <h2>4.0 Risks</h2>

      <h3>Competition</h3>
      <p>The clear aligner market has seen an influx of competitors, including Direct-to-Consumer (DTC) brands (though some like SmileDirectClub have faltered) and traditional dental companies (e.g., Straumann, Dentsply Sirona) offering their own aligner solutions.</p>

      <h3>Macroeconomic Sensitivity</h3>
      <p>Orthodontic treatment is often an elective, high-ticket expense. During economic downturns or periods of high inflation, consumer spending on elective procedures tends to decline, impacting Align's case volumes.</p>

      <h3>Patent Expirations</h3>
      <p>As key patents expire, generic competitors can enter the market more easily, potentially pressuring pricing and market share.</p>
    </section>

    <section class="doc-section">
      <h2>5.0 Related Pages</h2>

      <div class="integration-grid">
        <div class="integration-card">
          <h4><a href="../price-to-earnings-ratio.html">P/E Ratio</a></h4>
          <p>Understand why high-growth companies like ALGN trade at higher multiples.</p>
        </div>
        <div class="integration-card">
          <h4><a href="../return-on-equity.html">Return on Equity</a></h4>
          <p>Analyze Align's efficiency in generating profits from shareholder equity.</p>
        </div>
        <div class="integration-card">
          <h4><a href="../free-cash-flow.html">Free Cash Flow</a></h4>
          <p>See how Align's cash generation supports its share buyback program.</p>
        </div>
      </div>
    </section>

  </div>

  <footer class="doc-footer">
    <a href="../index.html">← Back to Investment Wiki</a>
    <span style="color: var(--text-tertiary);">Investment Wiki</span>
  </footer>

</div>

</body>
</html>
